OnCore Login

Sponsor-Investigators

Hope Rugo

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Status
Cancer Types
Breast
Locations
Alabama, California, Dana-Farber Cancer Institute, Duke Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Illinois, Maryland, Massachusetts, Mayo Clinic, Minnesota, North Carolina, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tennessee, The University of Chicago Medicine Comprehensive Cancer Center, UC San Francisco, University of Alabama at Birmingham Comprehensive Cancer Center, University of North Carolina Lineberger Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Washington, D.C.
Read more

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
Status
Closed
Cancer Types
Breast
Locations
Read more

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status
Open to Accrual
Cancer Types
Breast
Locations
California, Dana-Farber Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Illinois, Indiana, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Massachusetts, Pennsylvania, Tennessee, The University of Chicago Medicine Comprehensive Cancer Center, UC San Francisco, UPMC Hillman Cancer Center, Vanderbilt-Ingram Cancer Center, Washington, D.C.
Read more
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278